JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on January 30, 2004; DOI: 10.1124/jpet.103.059287


0022-3565/04/3092-816-824$20.00
JPET 309:816-824, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.059287v1
309/2/816    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Terashvili, M.
Right arrow Articles by Tseng, L. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Terashvili, M.
Right arrow Articles by Tseng, L. F.

NEUROPHARMACOLOGY

Differential Conditioned Place Preference Responses to Endomorphin-1 and Endomorphin-2 Microinjected into the Posterior Nucleus Accumbens Shell and Ventral Tegmental Area in the Rat

Maia Terashvili, Hsiang-en Wu, Randy J. Leitermann, Kuei-chun Hung, Andrew D. Clithero, Emma T. Schwasinger, and Leon F. Tseng

Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, Wisconsin

An unbiased conditioned place preference (CPP) paradigm was used to evaluate the reward effects of endogenous µ-opioid receptor ligands endomorphin-1 (EM-1) and endomorphin-2 (EM-2) from the mesolimbic posterior nucleus accumbens (Acb) shell and the ventral tegmental area (VTA) in CD rats. EM-1 (1.6-8.1 nmol) microinjected into posterior Acb shell produced CPP, whereas EM-2 (8.7-17.5 nmol) given into the same Acb shell produced conditioned place aversion (CPA). EM-1 (1.6-16.3 nmol) microinjected into the VTA produced CPP, whereas EM-2 (8.7 and 17.5 nmol) given into the same VTA site did not produce any effect, but at a high dose (35 nmol) produced CPP. EM-1 (3.3 nmol) or EM-2 (17.5 nmol) microinjected into the nigrostriatal substantia nigra was not significantly different from vehicle-injected groups. D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) at 94.13 pmol or 3-methoxynaltrexone at 0.64 pmol microinjected into the posterior Acb shell blocked EM-1-induced CPP and EM-2-induced CPA. At a higher dose, CTOP (941.3 pmol) and 3-methoxynaltrexone (6.4 pmol) produced CPA and CPP, respectively. Coadministration with antiserum against dynorphin A(1-17) (Dyn) (10 µg) microinjected into the posterior Acb shell blocked EM-2-induced CPA. However, it did not affect EM-1-induced CPP. It is concluded that EM-1 and EM-2 produce site-dependent CPP and CPA, respectively, by stimulation of different subtypes of µ-opioid-receptors; stimulation of one subtype of µ-opioid-receptor at the posterior Acb shell and VTA by EM-1 induces CPP, whereas stimulation of another subtype of µ-opioid receptor at the posterior Acb shell, but not the VTA, by EM-2 induces the release of Dyn to produce CPA.


Received August 28, 2003; accepted January 29, 2004.

Address correspondence to: Dr. Leon F. Tseng, Department of Anesthesiology, Medical College of Wisconsin, 8701 Watertown Plank Rd., Milwaukee, WI 53226. E-mail: ltseng{at}post.its.mcw.edu




This article has been cited by other articles:


Home page
J. Neurosci.Home page
E. B. Margolis, H. L. Fields, G. O. Hjelmstad, and J. M. Mitchell
{delta}-Opioid Receptor Expression in the Ventral Tegmental Area Protects Against Elevated Alcohol Consumption
J. Neurosci., November 26, 2008; 28(48): 12672 - 12681.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. Terashvili, L. F. Tseng, H.-e. Wu, J. Narayanan, L. M. Hart, J. R. Falck, P. F. Pratt, and D. R. Harder
Antinociception Produced by 14,15-Epoxyeicosatrienoic Acid Is Mediated by the Activation of {beta}-Endorphin and Met-Enkephalin in the Rat Ventrolateral Periaqueductal Gray
J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 614 - 622.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.